Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for splinter proof
Your search for splinterproof retrieved no results
A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion.
Peng P, Xu Y, Di Bisceglie AM, Fan X. Peng P, et al. BMC Res Notes. 2020 Sep 18;13(1):445. doi: 10.1186/s13104-020-05292-y. BMC Res Notes. 2020. PMID: 32948245 Free PMC article.
It combined 7-deaza-2'-deoxyguanosine 5'-triphosphate (c(7)dGTP)-involved primer extension, splinter-assisted intracellular cyclization, c(7)dGTP)-resistant enzymatic digestion, and two-phase rolling cycle amplification. ...TEEDseq achieved an HBV on-target rate of 3.31 0. …
It combined 7-deaza-2'-deoxyguanosine 5'-triphosphate (c(7)dGTP)-involved primer extension, splinter-assisted intracellular cyclizati …
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, Ferrero S. Genuardi E, et al. Hematol Oncol. 2021 Aug;39(3):293-303. doi: 10.1002/hon.2864. Epub 2021 Mar 31. Hematol Oncol. 2021. PMID: 33742718 Free PMC article. Clinical Trial.
Moreover, MRD by BCL2-TLA reached good sensitivity levels also in FL and was predictive of a primary refractory case. In conclusion, this study offers the proof of principle that TLA is a promising and reliable NGS-based technology for the identification of novel molecular …
Moreover, MRD by BCL2-TLA reached good sensitivity levels also in FL and was predictive of a primary refractory case. In conclusion, this st …
Restaging procedures, criteria of response, and relationship between pathological response and survival.
Splinter T, Denis L. Splinter T, et al. Semin Oncol. 1990 Oct;17(5):606-12. Semin Oncol. 1990. PMID: 2218573 Review.
The first priorities for upfront chemotherapy in TCCB are to prove in randomized phase III trials that the addition of toxic chemotherapy to toxic standard locoregional treatment can improve survival and/or permit bladder preservation. If such proof is obtained, we will ne …
The first priorities for upfront chemotherapy in TCCB are to prove in randomized phase III trials that the addition of toxic chemotherapy to …